ClinicalTrials.Veeva

Menu

Prevalence and Prognostic Relevance of Tricuspid Regurgitation in Different Heart Failure Entities

Charité University Medicine Berlin logo

Charité University Medicine Berlin

Status

Completed

Conditions

Heart Failure
Tricuspid Regurgitation

Study type

Observational

Funder types

Other

Identifiers

NCT04570098
EA1/178/19

Details and patient eligibility

About

The present study includes patients with tricuspid regurgitation and heart failure diagnosed with echocardiography. The aim is to evaluate the physical performance of patients with tricuspid regurgitation and heart failure, to observe the course of the diseases and to allow a better understanding of new therapy options.

Full description

Moderate to severe tricuspid regurgitation (TR) is a frequent result of left heart failure causing a limiting prognosis. The new interventional therapies have given more relevance to the questions of the prognostic significance of severe TR in the various heart failure entities.

Important but currently unanswered questions for the establishment of successful, interventional therapies of TR are:

  1. What effect does TR have on patients with heart failure?
  2. Which patients at which stage of the disease benefit from interventional TR-therapies? In order to answer these questions, the aim of the study is to prospectively record the prevalence of TR (including quantification) in all heart failure patients at the Charité, followed by long-term observation to assess its prognostic relevance.

In addition to answering the above-mentioned questions, the project will allow a central registration of all symptomatic heart failure patients. A comparative outcome analysis per propensity score matching with the untreated patients of the registry would allow to give first considerations which patients are ideal candidates for interventional therapies.

Primary endpoint: death Secondary endpoint: hospitalization due to cardiac decompensation, exercise capacity according to NYHA classification

Enrollment

1,016 patients

Sex

All

Ages

18 to 120 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with transthoracic echocardiography (TTE) and heart failure
  • Reported heart failure symptoms within the last two years
  • >18 years
  • Written, documented consent

Exclusion criteria

  • Patients in care or unable to consent

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems